Following the promising results observed in pre-clinical models, clinical trials with IFNα for human cancer treatment also showed efficacy in promoting regression of many tumor types (56), leading to IFNα2 approval as the first anticancer immunotherapy and its clinical use for many years to treat different cancers, including hematological malignancies (57, 58) and melanoma (59). The gene discussed is IFNA2; the disease is neoplasm.